Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Bioprostheses with pericardial leaflets mounted externally on the stent pose a high risk for valve-in-valve (ViV) procedures. This study analyzed the efficacy and safety of ViV procedures for treating structural valve deterioration (SVD) in Mitroflow bioprostheses.
Methods: Between January 2012 and August 2017, 11 patients (mean age 80.3 ± 5.6 years) were treated for SVD of Mitroflow bioprostheses with transcatheter ViV procedures (six transapical [TA] and five transfemoral [TF]) using balloon expandable bioprostheses.
Results: All patients but one were in NYHA class III-IV. Mean STS PROM, euroSCORE I, and euroSCORE II were 8 ± 6.5%, 27.8 ± 11.5%, and 12 ± 5.9%, respectively. Two patients had a "porcelain aorta." The size of implanted valves were 23 mm in 10 cases and 26 mm in one case. One patient suffered a coronary occlusion during a TF approach. The mean volume of contrast used in TF implants was 163 ± 69.8 mL. No contrast media were used in TA procedures. There was one in-hospital death (10%). At 1 year of follow-up, peak and mean aortic gradients were 25.5 ± 5.8 mmHg and 15.5 ± 5.7 mmHg, respectively. One patient had mild paravalvular regurgitation. Cumulative survival was 90.9% at 1 year, 70.7% at 2 years, and 53% at 3 years.
Conclusions: ViV procedures with balloon-expandable aortic valves provide good hemodynamic and clinical mid-term results for treating patients with a degenerated Mitroflow aortic bioprosthesis. Special care must be taken in small aortic roots, when the stented valve is in the supra-annular position to avoid coronary ostial obstruction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jocs.13720 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting the Surge in Valve-in-Valve Volume: A Comparative Study of Japan and the United States.
JACC Asia
August 2025
Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
Background: Understanding trends in transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) utilization is essential for predicting valve-in-valve (ViV) TAVR usage, a viable option for failed bioprosthetic valves that presents a promising avenue for lifetime management of aortic stenosis.
Objectives: This study aimed to predict and compare the future annual ViV volume in the United States and Japan based on past and current TAVR/SAVR utilization under some underlying assumptions.
Methods: We developed a MATLAB-based Monte Carlo model engine to simulate the lifespan of bioprosthetic TAVR and SAVR valves.
Transcatheter valve-in-valve mitral valve replacement with SAPIEN 3 valve for bioprosthetic mitral valve failure: one-year outcomes in 26 patients.
Zhejiang Da Xue Xue Bao Yi Xue Ban
August 2025
Department of Cardiovascular Surgery, Institute of Cardiovascular Surgery, West China Hospital, Sichuan University.
Objectives: To evaluate the one-year outcomes of valve-in-valve transcatheter mitral valve replacement (ViV-TMVR) using the SAPIEN 3 valve for treating mitral bioprosthetic valve failure.
Methods: A retrospective analysis was conducted on 26 patients with mitral bioprosthetic valve failure who underwent ViV-TMVR at West China Hospital, Sichuan University, between November 2022 and July 2024. The age of patients was 71.
Innovative dispersive liquid-liquid semi-microextraction approach for the speciation of V(IV) and V(V).
Anal Methods
August 2025
Department of Analytical and Toxicological Chemistry, Odesa National I.I. Mechnikov University, Vsevoloda Zmienka Str., 2, 65082, Ukraine.
The complexation of V(IV, V) species with 2,4-substituted derivatives of 6,7-dihydroxybenzopyrylium bromide has been studied. The stoichiometry of the interaction products in the studied systems M : L = 1 : 3 was established by classical spectrophotometric methods. It was shown that the introduction of phenyl substituents at positions 2 and 4 of the benzopyrylium fragment leads to a shift of complexation to a more acidic region, an increase in the stability of the reaction products, and an increase in their molar absorptivity.
View Article and Find Full Text PDF3-year outcomes following mitral Valve-in-Ring and Valve-in-Valve procedures.
Thorac Cardiovasc Surg
August 2025
Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.
Background In patients at elevated risk for redo mitral valve surgery, transcatheter mitral valve replacement (TMVR) can be taken into consideration as a less invasive alternative. However, long-term outcome data on mitral valve-in-ring (ViR) and valve-in-valve (ViV) procedures is scarce. We herein report the 3-year outcomes following these interventions.
View Article and Find Full Text PDFLive Hemodynamics-Assisted Simultaneous Aortic and Mitral Valve-in-Valve Replacement.
JACC Case Rep
July 2025
Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address:
Background: Bioprosthetic valve failure is a growing challenge, particularly in high-risk patients who are poor surgical candidates. Simultaneous valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve replacement (TMVR) via a fully percutaneous approach remains a novel and evolving strategy with limited data.
Case Summary: A 70-year-old man with failed aortic and mitral bioprostheses leading to severe intraprosthetic regurgitation presented with progressive heart failure symptoms.